ASND
Ascendis Pharma A/S
$270.45
-4.98 (-1.81%)
At close · Jul 10
Market Cap
$17.74B
Shares
65,592,830
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$270.45
Open$275.43
Day$267.85–276.91
52W$160.86–282.15
Avg vol 30d803K
Short int3.3M · 5.0% float · 2.5d
Short vol54%
Last earningsApr 8, 2026
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+13%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
90%
near high
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+26%
trailing
YTD return
+27%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $238 › 200d $222 — 50d above 200d
Institutional flow
Accumulating
8 of 282 funds reported for Jun 30 · net +89.3K sh shares · +2 new
Insider flow
Distributing
Net -$4.4M over 90 days · 33% sells
Short interest
Rising
5.00% of float · ▲ +65.0% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
282 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $238 › 200d $222 — 50d above 200d
Institutional flow
Accumulating
8 of 282 funds reported for Jun 30 · net +89.3K sh shares · +2 new
Insider flow
Distributing
Net -$4.4M over 90 days · 33% sells
Short interest
Rising
5.00% of float · ▲ +65.0% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
282 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $161
Now $270 · 90%
52-wk high $282
vs 200-day avg +22%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| new patients prescribed YORVIPATH during the quarter | 1,000 | Q1 2026 call | — |
| non-IFRS operating margin non-GAAP | 22% | Q1 2026 call | — |
| non-IFRS operating profit non-GAAP | 55M | Q1 2026 call | — |
| patients prescribed YORVIPATH through the end of March 2026 | 6,300 | through the end of March 2026 call | — |
| SKYTROFA share of the overall growth hormone market in the U.S. | 7% | Q1 2026 call | — |
| unique health care providers prescribing YORVIPATH through the end of March 2026 | 2,700 | through the end of March 2026 call | — |
| unique health care providers prescribing YUVIWEL since commercial availability | 35 | since YUVIWEL became commercially available in early April call | — |
| YUVIWEL children prescribed since commercial availability | 60 | since YUVIWEL became commercially available in early April call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASND
this stock
Ascendis Pharma A/S
|
$17.74B | +26.8% | — | — | 5.0% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
281
- % held
- 98.0%
- Reported
- 8 of 282
- Top holder
- RA CAPITAL MANAGEMENT, L.…
Held
Float
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASND | -1.5% | +28.9% | +25.8% | +1.4% | +26.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.9% | +24.8% | +16.7% | +0.3% | +16.1% |